^
    Apply
    Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer (NCT02167854)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    07/09/2021
    Initiation :
    06/16/2014
    Primary completion :
    07/07/2021
    Completion :
    07/07/2021
    HER-2 • PIK3CA
    |
    HER-2 amplification • PIK3CA mutation
    |
    Herceptin (trastuzumab) • Piqray (alpelisib) • elgemtumab (LJM-716)
    A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer (NCT01598077)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/19/2020
    Initiation :
    07/01/2012
    Primary completion :
    03/01/2014
    Completion :
    03/01/2014
    HER-2
    |
    elgemtumab (LJM-716)
    A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors (NCT01911936)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/17/2020
    Initiation :
    09/01/2013
    Primary completion :
    03/01/2015
    Completion :
    03/01/2015
    HER-2
    |
    HER-2 overexpression
    |
    elgemtumab (LJM-716)